ESMO 2020 - Grohé Poster

Efficacy and safety of nintedanib plus docetaxel in lung adenocarcinoma patients after failure of previous immune checkpoint inhibitor therapy: updated results from the ongoing non-interventional study VARGADO (NCT02392455)

Grohé C, Gleiber W, Haas S, Hammerschmidt S, Krüger S, Müller-Huesmann H, Schulze M, Wehler T, Atz J, Kaiser R

ESMO_2020_POSTER_IMAGE

Related articles

Learn more about the science behind this presentation in the papers and other materials below.

Nintedanib plus docetaxel after progression on immune checkpoint inhibitor therapy: insights from VARGADO, a prospective, non-interventional study in patients with lung adenocarcinoma

Grohé et al. Future Oncology 2019; DOI 10.2217/fon-2019-0262

Efficacy of nintedanib and docetaxel in patients with advanced lung adenocarcinoma treated with first-line chemotherapy and second-line immunotherapy in the nintedanib NPU program

Corral J et al. CTO 2019; DOI: 10.1007/s12094-019-02053-7

Nintedanib is approved in the EU under the brand name VARGATEF® for use in combination with docetaxel in adult patients with locally advanced, metastatic or locally recurrent NSCLC of adenocarcinoma tumor histology after first-line chemotherapy. For the full list of country-specific information please click here. Nintedanib is not approved in other oncology indications.

 

The materials for VARGATEF® (nintedanib) contained in this virtual exhibition page are approved for use only according to the European Union (EU) label as of August 2017. Prescribing information may vary depending on local approval in each country. Therefore, before prescribing any product, always refer to local materials such as the prescribing information and/or the Summary of Product Characteristics (SPC).

 

© 2020 Boehringer Ingelheim International GmbH. All rights reserved.

 

Page last updated: September 2020